This is a routine insider transaction following option exercise; monitor for actual execution via Form 4 filing. Given the officer status, follow-through could signal confidence or simply portfolio management, context from future filings will clarify.
RCUS drugs
RCUS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $23.28entry
- T+1 · 7mo ago −4.04%α −3.98% · $22.34
- T+5 · 7mo ago +1.33%α −1.85% · $23.59
- T+20 · 6mo ago +11.68%α +4.12% · $26.00
- T+60 · 4mo ago +28.78%α +18.00% · $29.98
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jennifer Jarrett, an officer of Arcus Biosciences, filed a Form 144 to notify intent to sell 70,000 shares of common stock, valued at approximately $1.58 million based on current market prices. The shares were acquired via stock option exercise and the sale is planned on the NYSE.
Key Facts
- Reporting person: Jennifer Jarrett, Officer
- Number of shares intended for sale: 70,000
- Approximate value of shares: $1,579,592 (based on $22.56/share)
- Shares acquired via: Stock option exercise
- Issuer: Arcus Biosciences, Inc. (RCUS)
- Filing date: April 8, 2026
- Planned transaction date: April 8, 2026
- Broker: Morgan Stanley Smith Barney LLC
Financial Impact
70,000 shares worth ~$1.58 million, representing a small fraction of the company's $2.8B market cap
Risk Factors
- Potential downward pressure on stock if sale executes near-term
- Perception of insider selling ahead of uncertain catalysts, though no such timing is indicated here
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003313 |
| Document: 0001950047-26-003313-index.html | 0001950047-26-003313 |
| Document: 0001950047-26-003313.txt | 0001950047-26-003313 |
Track record
13 reports on RCUS
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +4.24% at T+1 after the Oct 21, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $16.95 Now $16.86 −0.53% settles Nov 23
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $18.95 to $16.86 Now $16.86 −11.03% ▼ −11.03% −9.34% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $17.69 to $17.77 Now $16.86 −4.69% ▲ +0.45% −2.84% vs SPY
- Oct 23, 202624d ago 8-K Bearish 5/10 Entry $17.76 to $18.19 Now $16.86 +5.07% ▼ −2.42% −3.68% vs SPY
- Oct 22, 202625d ago 424B5 Bearish 6/10 Entry $18.54 to $18.19 Now $16.86 +9.06% ▲ +1.89% +1.33% vs SPY
- Oct 21, 202626d ago 424B5 Bearish 5/10 Entry $19.36 to $18.61 Now $16.86 +12.91% ▲ +3.87% +4.58% vs SPY
- Oct 21, 202626d ago 8-K Neutral 4/10 Entry $19.36 to $18.61 Now $16.86 −12.91% ▼ −3.87% −4.58% vs SPY
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $23.75 to $18.14 Now $16.86 −29.01% ▼ −23.62% −23.70% vs SPY
- Jul 9, 202618w ago 144 Neutral 3/10 Entry $28.92 to $26.64 Now $16.86 −41.70% ▼ −7.88% −7.32% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 2/10 Entry $26.62 to $24.55 Now $16.86 −36.66% ▼ −7.79% −7.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers